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Abstract
Background: Along with angioplasty, autologus vein grafts are commonly used for artery bypass
grafting in patients with advanced arterial stenosis and drug-resistant angina pectoris. Although
initially a successful procedure, long-term functionality is limited due to proliferation and migration
of smooth muscle cells. Like in atherosclerosis, common chronic infections caused by viruses and
bacteria may contribute to this process of vein graft failure. Here we investigated the possible role
of Chlamydia pneumoniae (Cpn) in the pathogenesis of venous graft failure in an experimental animal
model. In 2 groups (n = 10 rats/group), an epigastric vein-to-common femoral artery interposition
graft was placed. Immediately thereafter, rats were infected with Cpn (5*108 IFU) or injected with
control solutions. Rats were sacrificed three weeks after surgery and the grafts were harvested for
morphometrical and immunohistochemical analysis.
Results: Cpn administration immediately after vein grafting resulted in a significant increase in
medial cross-sectional area, wall thickness and total wall area. There were no significant differences
in T-cell or macrophage influx. Likewise, although positive immunostaining for both HSP60 and
CRP could be detected, no differences were found between groups. Based on the observation that
the number of cells/µm2 was also not altered, we conclude that Cpn infection stimulates smooth
muscle cell proliferation by hereunto unknown molecular mechanisms, resulting in a significant
increase in intimal hyperplasia.
Conclusion: In conclusion, in a well defined animal model we present here for the first time
evidence for a role of Chlamydia pneumoniae in the process of venous graft failure.
Background
Besides internal mammary arteries, autologus saphenous
vein grafts are commonly used for coronary artery bypass
grafting (CABG) in angina pectoris patients, resistant to
aggressive medical therapy or patients with advanced cor-
onary artery stenosis not suitable for percutaneous trans-
luminal coronary angioplasty (PTCA). Although the
initial results of venous grafts are excellent, the symptoms
tend to recur due to vein graft degeneration and stenosis
greatly limiting the long term success of bypass surgery.
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Early failure occurs within the first 1 to 2 months proba-
bly from primary thrombosis often due to technical fail-
ure or poor runoff in severely stenotic distal coronary
arteries [1]. Late failure occurs from several months to
years after bypass surgery and is caused by neointimal
hyperplasia (NIH) with subsequent atherosclerosis in the
saphenous vein graft [2]. NIH, defined as the accumula-
tion of phenotypically altered medial smooth muscle cells
(SMC) and extracellular matrix in the intimal component
of the vein, is most prominent in the venous graft within
the first year. Several factors interact to influence the
development of NIH mostly initiated by ischemia of the
venous wall, mechanical trauma and hemodynamic
stress. Moreover, convincing evidence suggested that NIH
is associated with extensive endothelial denudation and
destruction of venous grafts [3], resembling a response to
injury as seen after angioplasty often leading to restenosis
of the denuded artery.
Today it is generally accepted that atherosclerosis is an
inflammatory diseases and that atherogenesis as well as
disease progression result from inflammation and
immune responses towards various stimuli. Common
chronic infections caused by viruses and bacteria have
been suggested to contribute to this inflammatory proc-
ess. Most compelling evidence comes from data concern-
ing the intracellular pathogen Chlamydia pneumonia
(Cpn). Although this bacterium was initially identified as
a causative factor in (a-)symptomatic inflammation of the
airways, clinical studies demonstrated that patients with
high titers of antibody against Cpn have an increased risk
for cardiovascular complications [4,5]. This is supported
by studies revealing significant accelerations of lesion
development in animals and a large variety of pro-athero-
genic effects in vitro [6-8]. In addition, recent studies have
shown that Cpn infection promotes a proliferative pheno-
type in the vasculature, which makes Cpn also a likely risk
factor for vein graft failure [9,10]. This is supported by the
work of Bartels et al., who observed a strong correlation
between elevated Cpn IgG titers and the detection of Cpn
in occluded vein grafts [11]. Similar data were shown by
Zorc et al., implicating a possible relationship between
Cpn  presence and occluded arterial bypass grafts [12].
These studies suggest that Cpn  is present in occluded
grafts, however, experimental evidence for this is currently
lacking. In the present paper we addressed this by examin-
ing the contribution of Cpn to neointimal hyperplasia in
a well defined animal model for autologous vein grafting.
To our knowledge this is the first paper which addresses
the possible contribution of Cpn infection to the patho-
genesis of venous graft failure in an experimental model.
Results
Animal condition and grafts
Starting body weight ranged from 250 g to 350 g, while at
the end of the experimental period animal weight ranged
from 320 g to 400 g. No differences in body weight were
observed between experimental groups. During the exper-
imental phase no apparent clinical signs of illness were
observed in any of the animals. The overall graft patency
after three weeks was 90%. Early thrombosis seemed the
underlying cause of the failed grafts. No structural anom-
alies at the anastomotic regions of the grafts were
observed.
Chlamydia pneumoniae aggravates intimal hyperplasia 
through stimulation of SMC proliferation
Three weeks after bypass grafting in all veins a significant
increase in medial thickness was observed (medial thick-
ness in normal, non-grafted vein: 10 ± 2 µm vs. 36 ± 3 µm
in grafted vein of the control group) and showed neointi-
mal thickening, which is principally absent in non-grafted
control veins.Cpn administration immediately after vein
grafting resulted in a significant increase in the medial
thickness (Cpn-group: 50 ± 3 µm vs. control group: 36 ± 3
µm, p ≤ 0.05), total wall cross-sectional area (Cpn-group:
184200 ± 57932 µm2 vs. control group: 75359 ± 15473
µm2, p ≤ 0.05) and medial cross-sectional area (Cpn-
group: 101731 ± 22984 µm2 vs. control group: 54149 ±
13960 µm2, p ≤ 0.05) at 3 weeks post surgery (Figure 1).
Next, we tried to determine whether the increase in cross-
sectional area results from a concomitant increase in cell
number or whether the increase is due to cellular hyper-
trophy, interstitial oedema or an increase in extracellular
matrix components. Therefore, we determined cellular
density. Our finding that the average number of cells/µm2
was not significantly different between groups (Cpn-
group: 5.0 ± 0.7 × 10-3 cells/µm2 vs. control group: 4.1 ±
0.5 × 10-3 cells/µm2), suggests that Cpn infection stimu-
lates cell proliferation but not cellular hypertrophy or
interstitial oedema or an increase in extracellular matrix
components. After all, the latter are expected to reduce cel-
lular density, a phenomenon which was not observed.
Influx of inflammatory cells
Staining for inflammatory cells in the venous graft
showed a minimal influx of T-cells at three weeks after
surgery with an average of one to three T-cells per cross-
section. No significant differences between experimental
groups were observed. On the other hand, macrophages
were notably present in the subendothelial area and in the
media, however with a with a wide variance. Therefore, no
significant differences between groups were found. More-
over, alpha-actin staining showed SMC to be the main
content of the intima and media with little extra-cellular
matrix accumulation in both groups, confirming that theBMC Microbiology 2007, 7:111 http://www.biomedcentral.com/1471-2180/7/111
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increase in wall mass is predominantly due to smooth
muscle cell proliferation.
C-reactive protein
We also performed an immunostaining to reveal the pres-
ence of C-reactive protein (CRP) in the venous graft.
Although predominantly produced by the liver, local pro-
duction of CRP by SMC in response to inflammatory
cytokines has also been demonstrated recently [13]. Also,
evidence suggests that CRP is involved in smooth muscle
cell migration and proliferation [14]. Truly, positive stain-
ing for CRP could be detected mainly in the subendothe-
lial area (typical example shown in Figure 2A).
Nonetheless, when stainings were quantified in a semi-
quantitative manner, no significant differences were
observed between groups (Cpn-infected: 2.5 ± 0.8 v.s. con-
trol group 2.4 ± 0.5, n.s.).
Heat shock protein 60
Previously we demonstrated the noticeable presence of
heat shock protein 60 (HSP60) in occluded veins [15].
Furthermore, we were able to demonstrate that HSP60 is
able to stimulate SMC proliferation in a TLR2/4 depend-
ent way [15]. To determine whether HSP60 also plays a
role in graft failure in the present model and whether Cpn
affects the presence of HSP60 in the grafts, we stained
HSP60 in grafts from both the control group and the Cpn-
infected group. Indeed, HSP60 positive staining could be
revealed in both groups (typical example shown in Figure
2C). Also, semi-quantitative analysis showed a trend
towards a more intense HSP60 signal in the Cpn-infected
group (Cpn-group: 3.3 ± 0.5 v.s. control group: 2.8 ± 0.7,
n.s.), although the difference was not statistically signifi-
cant.
Discussion
Saphenous vein graft failure is a common problem after
CABG. Approximately 15% to 30% of vein grafts occlude
during the first year increasing up to 50% within 10 years
[16]. Graft failure occurring within one month after sur-
gery is almost always caused by thrombosis. Neointimal
hyperplasia as defined as the accumulation of SMC and
extracellular matrix in the intimal layer follows a similar
pattern in the balloon injured artery or vein graft and is
the major disease process in the vein graft resulting in fail-
ure during the first year [17]. Nearly all veins implanted
into the arterial circulation develop intimal wall thicken-
ing thereby reducing the lumen size. This is confirmed by
our results in the rat venous graft model. At 3 weeks post
transplantation, a significant increase in both total and
medial cross-sectional area as well as media thickness was
observed in the epigastric vein grafts, which is in agree-
ment with earlier data from Hoch and colleagues [18].
To unravel the underlying molecular mechanisms con-
tributing to the pathology of vein graft failure a large vari-
ety of studies have been carried out of the past decades in
order to find an effective intervention. However, until
now these mechanisms haven't been completely eluci-
dated yet. Recently, sero-epidemiologic studies have sug-
gested a role for Cpn the development of vascular disease.
Cpn  is an obligatory intracellular Gram-negative bacte-
rium that was first isolated as a respiratory pathogen. This
micro-organism has also been isolated from coronary
arteries of patients with acute coronary syndrome [12], as
well as from carotid arteries [19], the aorta and peripheral
arteries [20]. These observations in combination with
multiple in vitro findings [7] demonstrating a stimulating
effect of Cpn on SMC proliferation, supported a role for
Cpn in obstructive vascular disease. Nonetheless, in con-
trast to atherosclerosis, a possible role of Cpn in venous
bypass failure has been less subject of study. Bartels et
al.[21] studied the prevalence of Cpn in occluded vein
Effect of Cpn administration on total wall (A) cross-sectional  area, medial cross-sectional area (B) and wall thickness (C)  three weeks after vein grafting Figure 1
Effect of Cpn administration on total wall (A) cross-sectional 
area, medial cross-sectional area (B) and wall thickness (C) 
three weeks after vein grafting. * P < 0.05 (values compared 
with control).
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grafts and native saphenous veins and showed that Cpn
was frequently present in occluded CABG but not in nor-
mal veins. Cpn DNA could be detected by PCR in 25% of
the cases, while viable Cpn was recovered from 16% of
occluded vein grafts. In this study we present for the first
time evidence for a role for Cpn in venous graft failure.
When rats were infected with Cpn immediately after sur-
gery, a significant increase in media thickness and total
wall cross-sectional area was observed in the epigastric
vein-to-common femoral artery graft. To unravel a poten-
tial mechanism which might explain the effect of Cpn on
intima hyperplasia, we first evaluated the presence of
inflammatory cells in the graft. Focal endothelial disrup-
tion, occurring during all vein graft harvesting, leads to
adherence of platelets and monocytes. Several lines of evi-
dence suggest that Cpn replicate within alveolar cells and
can make its way into the wall of the healing graft by using
macrophages and monocytes as vectors [22]. Once
present in the vascular wall, Cpn may further enhance the
influx of monocytes through the release of monocyte che-
moattractant protein 1 by VSMC's. Chronic macrophage
infection contributes to local inflammation but it remains
unclear whether this aggravates intimal hyperplasia and
bypass failure. Hoch et al. demonstrated that depletion of
macrophages suppresses intimal hyperplasia indicating
the importance of the amount of macrophages present in
the graft [18]. However immunostaining of the venous
graft in our model showed no differences in influx of
inflammatory cells between the Cpn infected and the con-
trol group, suggesting a different mechanism of action.
Cpn infection of vascular smooth muscle cells increases
interleukin-6 (IL-6) secretion in vitro [23]. In vivo, IL-6 is
a strong inducer of liver C-reactive protein (CRP) produc-
tion which is able to stimulate endothelial and smooth
muscle cell proliferation providing a pathway for Cpn to
aggravate vein graft failure [24]. In addition, evidence is
Photomicrographs showing subsequent immunolabeling of a venous bypass graft 3 weeks after surgery (A: CRP, C:HSP60) as  well as their representative negative controls (B, D) Figure 2
Photomicrographs showing subsequent immunolabeling of a venous bypass graft 3 weeks after surgery (A: CRP, C:HSP60) as 
well as their representative negative controls (B, D).
A
B D
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accumulating suggesting that SMC are able to produce
CRP and stimulate SMC migration and proliferation in an
autocrine fashion [14]. Indeed, we were able to demon-
strate the presence of CRP in particular in the sub-
endothelial layer thereby providing further evidence for a
role for CRP in intima hyperplasia. Nonetheless, no differ-
ence between the two groups were observed indicating
that Cpn infection does not have an effect on the presence
of CRP in the vascular wall at the time point examined.
Nevertheless, this does not exclude that Cpn may affect the
production of CRP at earlier time points post surgery and
contribute as such to the process already at an earlier
stage. Further studies are required to unravel this aspect in
more detail.
Cpn  is also known to produces large amounts of heat
shock protein 60 (HSP 60) during chronic, persistent
infections [25]. Cpn HSP60, which is well conserved dur-
ing evolution and shows a high degree of homology with
mammalian HSP60, is able to activate vascular endothe-
lium, smooth muscle cells, and macrophages [26]. HSP60
is also able to stimulate SMC proliferation [15,27] and
may hereby aggravate a hyperplastic response as seen in
our model. Therefore, we decided to determine the pres-
ence of HSP60 by immunohistochemistry. Actually we
were well able to visualize the presence of HSP60 in the
grafts of both groups; however, despite the fact that there
was a trend towards an increase in the presence of HSP 60
in the venous grafts of the Cpn-infected group as com-
pared to the controls, this failed to reach statistical signif-
icance.
Conclusion
Summarizing, we present here for the first time evidence
for a possible role of Chlamydia pneumoniae in the process
of venous graft failure. In a well defined animal model, a
significant increase in both total and media cross-sec-
tional area as well as media thickness was observed in vein
grafts obtained from Cpn-infected rats, suggesting that Cpn
is able to promote the process of intima hyperplasia. Fur-
thermore, cellular density in the vascular wall remained
constant indicating that Cpn stimulates cell proliferation
but not hypertrophy nor the formation of institial oedema
or the deposition of extracellular matrix components. In
addition, we analyzed in more details some of the possi-
ble molecular mechanisms which may contribute to the
observed Cpn-mediated effects. However, none of the sug-
gested mechanisms (enhanced influx of inflammatory
cells, augmented production of CRP or HSP60) seemed
primarily responsible for the observed effects and further
research is warranted to elucidate in more detail how Cpn
affects vein graft failure.
Methods
Animals and Vein Grafting Procedure
Male inbred specific pathogen free (SPF) male Lewis
(LEW) rats were obtained form the Department of Exper-
imental Animal service of the University of Maastricht, the
Netherlands. Experiments were carried out on animals
aged 12 weeks weighing 250–350 gram. Housing and care
of the animals, and all the procedures used in this study
were approved by the Ethical Committee for the Use of
Experimental Animals of the institution, and conform the
Guide for the Care and the Use of Laboratory Animals,
published by the US National Institute of Health (NIH
Publication No. 85-23, revised 1985). Rats were fed stand-
ard rat chow and tap water at libitum. All surgical proce-
dures were performed under general anesthesia and using
sterile techniques. Epigastric vein-to-common femoral
artery interposition grafts were placed in rats in a similar
way as previously described by Hoch et al.[28]. In brief,
each animal was anesthetized with an intraperitoneal
(i.p.) injection of pentobarbital sodium (60 mg/kg). An 8
mm segment of ipsilateral epigastric vein was carefully
harvested, gently irrigated with heparinized saline solu-
tion (100 U/ml), and placed as reverse interposition graft
into a segmental 3 mm defect of the common femoral
artery with 8 to 10 interrupted sutures of 11-0 nylon
(Ethicon). The entire procedure was carried out with
standard microsurgical techniques. The total ischemic
time was kept to less than 30 min. Graft patency, defined
as a condition of flow through the graft, was verified by
visual inspection at the end of the surgical procedure.
Experimental Design
Two experimental groups were used. Directly after the
grafting procedure, rats (n = 10 animals/group) were
either Cpn-infected by i.p. injection (1 ml of 5 × 108 inclu-
sion forming units (IFU) dissolved in a sucrose-phos-
phate-glucose solution) or received a 1 ml i.p. injection of
a sucrose-phosphate-glucose solution. The i.p. inocula-
tion route instead of the intranasal route was used because
of the high infectious dosage required in rat experiments.
Previous experiments done in our laboratory have dem-
onstrated no significant differences in systemic dissemina-
tion of Cpn  between intranasal and i.p. injection
(Ezzahiri, personal communication).
Histological and morphometrical procedures
Three weeks after surgery, rats were anaesthetized, the
chest and abdominal cavities were opened and a catheter
was inserted into the apex of the heart. Vessels were ini-
tially flushed with physiological salt solution and then
perfusion fixed with 3,7% formaldehyde in phosphate-
buffered saline (PBS, pH 7.4) at physiological pressure
(100 mmHg). Vein grafts were removed and fixed over-
night in the same fixative and routinely processed for par-
affin embedding. Cross-sections (4 µm) wereBMC Microbiology 2007, 7:111 http://www.biomedcentral.com/1471-2180/7/111
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haematoxylin-eosin or Lawson stained for morphometri-
cal analysis (average of three cross-sections per graft). Inti-
mal and medial areas were quantified using a computer-
assisted morphometry system (analySIS®, Soft Imaging
System, GmbH). The cross-sectional area of the media was
defined as the area surrounded by the external and inter-
nal elastic lamina. The neointimal cross-sectional area was
defined by the area surrounded by the internal elastic lam-
ina and the arterial lumen. Final scores were given as
means ± SEM.
Quantification of cell number in the intima and media
The number of cells in the intima and media was quanti-
fied by counting the total number of nuclei using a micro-
scope. All nuclei were counted in haematoxylin-eosin
stained cross-sections. Final scores were expressed as
number of cells per area and values are given as means ±
S.E.M
Immunohistochemistry
Paraffin sections (4 µm), taken from vein grafts three
weeks after surgery, were routinely processed and stained
with the two-layer indirect immunoperoxidase technique
using monoclonal antibodies (mAb).
The following mAbs were used in this study: Anti-rat CD3
(Sera-lab, Crawley Down, UK), a mouse mAb against T-
cells; anti-α smooth muscle actin (ASMA, Sigma, Mis-
souri, USA), ED-1, a mouse mAb to monocytes/macro-
phages (kindly supplied by Dr. A.M. Duijvestijn Dept. of
Immunology, University Maastricht, the Netherlands), a
rabbit anti-HSP60 (CST, Danvers, USA) and anti-CRP
(R&D systems, Minneapolis, USA) a mouse mAb against
C-reactive protein.
Sections were incubated with 2% BSA/PBS (ED-1, CRP
and ASMA) for 15 min at room temperature and treated
with antigen retrieval buffer (CD3) for 25 min at 95°C
[13]. Sections for HSP60 staining were incubated with 10
mM sodium citrate buffer pH 6.0 and microwave boiled
for 10 min at 95–99°C. Monoclonals were diluted (ED-1
1/20, ASMA 1/1500, CD3 1/400, CRP 1/100) in PBS and
applied to the slides for 60 min at 37°C. HSP60 mono-
clonals were diluted 1/100 in PBS and applied to the
slides overnight at 4°C. After three wash steps with PBS
for 5 min, a biotinylated goat anti-mouse secondary anti-
body (1/1200, DAKO Glostrup Denmark) was applied for
30 min at room temperature. Finally, sections were incu-
bated with alkaline phosphatase-coupled streptavidin
(ABC reagent, Vector Laboratories), followed by immun-
odetection using fast red as a substrate. To visualize
nuclei, sections were counterstained with haematoxylin.
Then, the presence of positive cells was analyzed by
microscopy and scored semi-quantitatively, using a zero
to four scale with zero meaning no positive signal and 4
extremely positive, by an observer blinded to the experi-
mental groups. Final values were expressed as mean ±
S.E.M.
Statistical analysis
Morphometrical data and cell count numbers are
expressed as means ± S.E.M. Values were compared using
the Mann Whitney U test and p < 0.05 was considered as
statistically significant.
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